2024 NaviFUS FUS Symposium Videos Now Available!
In 2024 September 22nd, we hosted the NaviFUS FUS Symposium, featuring groundbreaking advancements in NaviFUS technology and clinical research. Over 240 participants from around the world joined us for sessions on BBB Opening, Neuromodulation, and New Treatments, along with insightful panel discussions.
We’re excited to announce that all session recordings are now available on our Symposium YouTube channel! Don’t miss out on these transformative insights.
Technology System
NaviFUS has two products in development：
NaviFUS® Neuronavigator-guided transcranial focused ultrasound system
NaviFUS® – FUS system that uses ultrasound energy to open the BBB and for neuromodulation; the device has already passed preliminary safety testing.
NAVIRFA® Needle Tracking System
Precise Surgical Tracking Technology
NAVIRFA® – Optical 3D surgical guidance kit and software that can accurately visualize the spatial position of surgical needles in vivo through special imaging algorithms.
Partners & Investors
We are supported by great venture capital and healthcare investors, and we partner with international distributors, physicians, medical institutions, academic researchers, and patient advocacy groups around the world.
OUR PARTNERSHIPSINVESTOR RELATIONS
NaviFUS Latest News
See what we’ve been up to.
Children’s National Advances Pediatric Brain Tumor Research with NaviFUS Focused Ultrasound Platform
Children’s National Hospital is advancing new possibilities in pediatric brain tumor care through expanded focused ultrasound research using the NaviFUS neuronavigation-guided low-intensity focused ultrasound (LIFU) platform. The collaboration supports ongoing efforts to explore non-invasive therapeutic approaches for children with difficult-to-treat brain tumors.
Read more
Focused Ultrasound for Glioblastoma (GBM): Clinical Results and Follow-On Trial in Clinical Results
Key Points：
-Researchers in Taiwan completed an early-stage trial showing focused ultrasound–mediated blood-brain barrier opening plus chemotherapy is safe in patients with GBM.
– The investigators are now recruiting participants for a larger clinical trial with the same device – the NaviFUS system – at two sites.
NaviFUS Presents Promising Stroke Rehabilitation Data at AOCCN 2025
Taipei, Taiwan – November 25, 2025 – At the 8th Asian–Oceanian Congress of Clinical Neurophysiology (AOCCN 2025) in Taipei, NaviFUS Corp. (6872) announced encouraging early clinical data showing that its neuronavigation-guided focused ultrasound (FUS) system is expanding beyond epilepsy into the field of stroke rehabilitation.
Read moreJoin Our Clinical Trials
NaviFUS is now enrolling participants for a new, non-invasive treatment using focused ultrasound for drug-resistant epilepsy and brain tumors.
No surgery. New hope.
Contact NaviFUS
Thank you for your interest in NaviFUS.
Feel free to contact us with any questions regarding collaboration.